Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Senescent human hematopoietic progenitors show elevated expression of transposable elements and inflammatory genes.

Capone S, Connor KM, Colombo A, Li X, Triche TJ Jr, Ramsingh G.

Exp Hematol. 2018 Jun;62:33-38.e6. doi: 10.1016/j.exphem.2018.03.003. Epub 2018 Mar 13.

PMID:
29549053
2.

Author Correction: Suppression of Transposable Elements in Leukemic Stem Cells.

Colombo AR, Zubair A, Thiagarajan D, Nuzhdin S, Triche TJ, Ramsingh G.

Sci Rep. 2018 Mar 6;8(1):4240. doi: 10.1038/s41598-018-21280-6.

3.

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ Jr, Druker BJ, Tyner JW, Gill PS.

Blood Adv. 2017 Aug 28;1(20):1635-1644. doi: 10.1182/bloodadvances.2017005694. eCollection 2017 Sep 12.

4.

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.

Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B.

Clin Epigenetics. 2017 Oct 5;9:108. doi: 10.1186/s13148-017-0411-x. eCollection 2017.

5.

Suppression of Transposable Elements in Leukemic Stem Cells.

Colombo AR, Zubair A, Thiagarajan D, Nuzhdin S, Triche TJ, Ramsingh G.

Sci Rep. 2017 Aug 1;7(1):7029. doi: 10.1038/s41598-017-07356-9. Erratum in: Sci Rep. 2018 Mar 6;8(1):4240.

6.

GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.

Chaudhry P, Singh M, Triche TJ, Guzman M, Merchant AA.

Blood. 2017 Jun 29;129(26):3465-3475. doi: 10.1182/blood-2016-05-718585. Epub 2017 May 9.

PMID:
28487292
7.

Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi.

Fortin JP, Triche TJ Jr, Hansen KD.

Bioinformatics. 2017 Feb 15;33(4):558-560. doi: 10.1093/bioinformatics/btw691.

8.

A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families.

Li WL, Buckley J, Sanchez-Lara PA, Maglinte DT, Viduetsky L, Tatarinova TV, Aparicio JG, Kim JW, Au M, Ostrow D, Lee TC, O'Gorman M, Judkins A, Cobrinik D, Triche TJ.

J Mol Diagn. 2016 Jul;18(4):480-93. doi: 10.1016/j.jmoldx.2016.02.006. Epub 2016 May 4.

9.

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Hingorani P, Missiaglia E, Shipley J, Anderson JR, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, Skapek SX.

Clin Cancer Res. 2015 Oct 15;21(20):4733-9. doi: 10.1158/1078-0432.CCR-14-3326.

10.

Insulin-like Growth Factor 2 Gene Expression Molecularly Differentiates Pleuropulmonary Blastoma and Embryonal Rhabdomyosarcoma.

Venkatramani R, Triche TJ, Wang L, Shimada H, Mascarenhas L.

J Pediatr Hematol Oncol. 2015 Aug;37(6):e356-60. doi: 10.1097/MPH.0000000000000382.

11.

Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group.

Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER.

J Pathol Clin Res. 2015 Apr;1(2):83-94.

12.

Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line.

Moore JB 4th, Loeb DM, Hong KU, Sorensen PH, Triche TJ, Lee DW, Barbato MI, Arceci RJ.

Front Cell Dev Biol. 2015 Mar 9;3:15. doi: 10.3389/fcell.2015.00015. eCollection 2015.

13.

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.

Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP.

Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.

14.

Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer.

Mitra AP, Lam LL, Ghadessi M, Erho N, Vergara IA, Alshalalfa M, Buerki C, Haddad Z, Sierocinski T, Triche TJ, Skinner EC, Davicioni E, Daneshmand S, Black PC.

J Natl Cancer Inst. 2014 Oct 24;106(11). pii: dju290. doi: 10.1093/jnci/dju290. Print 2014 Nov.

15.

DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.

Shah ED, Fisch BM, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP.

Cancer Chemother Pharmacol. 2014 May;73(5):1089-93. doi: 10.1007/s00280-014-2433-9. Epub 2014 Mar 25.

PMID:
24663501
16.

Reprogramming of the human intestinal epigenome by surgical tissue transposition.

Lay FD, Triche TJ Jr, Tsai YC, Su SF, Martin SE, Daneshmand S, Skinner EC, Liang G, Chihara Y, Jones PA.

Genome Res. 2014 Apr;24(4):545-53. doi: 10.1101/gr.166439.113. Epub 2014 Feb 10.

17.

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.

May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP.

PLoS One. 2013 Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060. eCollection 2013.

18.

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):64-9. doi: 10.1038/pcan.2013.49. Epub 2013 Oct 22.

19.

The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.

Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM.

Nat Genet. 2013 Nov;45(11):1392-8. doi: 10.1038/ng.2771. Epub 2013 Sep 29.

20.

Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosis.

Wiseman SM, Haddad Z, Walker B, Vergara IA, Sierocinski T, Crisan A, Ghadessi M, Dao P, Zimmermann B, Triche TJ, Erho N, Davicioni E.

J Clin Endocrinol Metab. 2013 Oct;98(10):4072-9. doi: 10.1210/jc.2013-1991. Epub 2013 Aug 8.

PMID:
23928671
21.

A novel algorithm for simplification of complex gene classifiers in cancer.

Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, Anderson JR, Skapek SX, Volchenboum SL.

Cancer Res. 2013 Sep 15;73(18):5625-32. doi: 10.1158/0008-5472.CAN-13-0324. Epub 2013 Aug 2.

22.

TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.

Fam HK, Walton C, Mitra SA, Chowdhury M, Osborne N, Choi K, Sun G, Wong PC, O'Sullivan MJ, Turashvili G, Aparicio S, Triche TJ, Bond M, Pallen CJ, Boerkoel CF.

Mol Cancer Res. 2013 Oct;11(10):1179-92. doi: 10.1158/1541-7786.MCR-12-0575. Epub 2013 Aug 2.

23.

VlincRNAs controlled by retroviral elements are a hallmark of pluripotency and cancer.

St Laurent G, Shtokalo D, Dong B, Tackett MR, Fan X, Lazorthes S, Nicolas E, Sang N, Triche TJ, McCaffrey TA, Xiao W, Kapranov P.

Genome Biol. 2013 Jul 22;14(7):R73. doi: 10.1186/gb-2013-14-7-r73.

24.

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB.

PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.

25.

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB.

J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.

26.

ERBB4 confers metastatic capacity in Ewing sarcoma.

Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH.

EMBO Mol Med. 2013 Jul;5(7):1087-102. doi: 10.1002/emmm.201202343. Epub 2013 May 16.

27.

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G.

N Engl J Med. 2013 May 30;368(22):2059-74. doi: 10.1056/NEJMoa1301689. Epub 2013 May 1. Erratum in: N Engl J Med. 2013 Jul 4;369(1):98.

28.

Low-level processing of Illumina Infinium DNA Methylation BeadArrays.

Triche TJ Jr, Weisenberger DJ, Van Den Berg D, Laird PW, Siegmund KD.

Nucleic Acids Res. 2013 Apr;41(7):e90. doi: 10.1093/nar/gkt090. Epub 2013 Mar 9.

29.

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA.

PLoS One. 2013;8(1):e54556. doi: 10.1371/journal.pone.0054556. Epub 2013 Jan 24.

30.

Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer.

Erho N, Buerki C, Triche TJ, Davicioni E, Vergara IA.

J Oncol. 2012;2012:541353. doi: 10.1155/2012/541353. Epub 2012 Aug 16.

31.

Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers.

Vergara IA, Erho N, Triche TJ, Ghadessi M, Crisan A, Sierocinski T, Black PC, Buerki C, Davicioni E.

Front Genet. 2012 Feb 22;3:23. doi: 10.3389/fgene.2012.00023. eCollection 2012.

32.

An epigenomic mechanism in retinoblastoma: the end of the story?

Murphree AL, Triche TJ.

Genome Med. 2012 Feb 24;4(2):15. doi: 10.1186/gm314.

33.

A central role for long non-coding RNA in cancer.

Mitra SA, Mitra AP, Triche TJ.

Front Genet. 2012 Feb 15;3:17. doi: 10.3389/fgene.2012.00017. eCollection 2012.

34.

Influence of RNA labeling on expression profiling of microRNAs.

Kaddis JS, Wai DH, Bowers J, Hartmann N, Baeriswyl L, Bajaj S, Anderson MJ, Getts RC, Triche TJ.

J Mol Diagn. 2012 Jan;14(1):12-21. doi: 10.1016/j.jmoldx.2011.08.005. Epub 2011 Nov 7.

35.

The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis.

Ng TL, Leprivier G, Robertson MD, Chow C, Martin MJ, Laderoute KR, Davicioni E, Triche TJ, Sorensen PH.

Cell Death Differ. 2012 Mar;19(3):501-10. doi: 10.1038/cdd.2011.119. Epub 2011 Sep 23.

36.

Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.

Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS.

J Clin Oncol. 2011 Apr 1;29(10):1304-11. doi: 10.1200/JCO.2010.29.4611. Epub 2011 Feb 28.

37.

The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA.

Kapranov P, St Laurent G, Raz T, Ozsolak F, Reynolds CP, Sorensen PH, Reaman G, Milos P, Arceci RJ, Thompson JF, Triche TJ.

BMC Biol. 2010 Dec 21;8:149. doi: 10.1186/1741-7007-8-149. Erratum in: BMC Biol. 2011;9:86.

38.

Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.

Cooper A, van Doorninck J, Ji L, Russell D, Ladanyi M, Shimada H, Krailo M, Womer RB, Hsu JH, Thomas D, Triche TJ, Sposto R, Lawlor ER.

Clin Cancer Res. 2011 Jan 1;17(1):56-66. doi: 10.1158/1078-0432.CCR-10-1417. Epub 2010 Nov 3.

39.

Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.

Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jürgens H, Pollak MN, Aparicio SA, Sorensen PH.

Cancer Res. 2010 Nov 1;70(21):8770-81. doi: 10.1158/0008-5472.CAN-10-1093. Epub 2010 Oct 19.

40.

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Molyneux SD, Di Grappa MA, Beristain AG, McKee TD, Wai DH, Paderova J, Kashyap M, Hu P, Maiuri T, Narala SR, Stambolic V, Squire J, Penninger J, Sanchez O, Triche TJ, Wood GA, Kirschner LS, Khokha R.

J Clin Invest. 2010 Sep;120(9):3310-25. doi: 10.1172/JCI42391. Epub 2010 Aug 9.

41.

Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ.

J Clin Oncol. 2010 Oct 10;28(29):e587-8; author reply e589-90. doi: 10.1200/JCO.2010.30.5466. Epub 2010 Aug 9. No abstract available.

PMID:
20697086
42.

Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells.

Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH.

Mol Cancer Ther. 2010 May;9(5):1396-407. doi: 10.1158/1535-7163.MCT-09-0604. Epub 2010 Apr 27.

43.

CD133 expression in chemo-resistant Ewing sarcoma cells.

Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER.

BMC Cancer. 2010 Mar 26;10:116. doi: 10.1186/1471-2407-10-116.

44.

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.

van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER.

J Clin Oncol. 2010 Apr 20;28(12):1989-94. doi: 10.1200/JCO.2009.24.5845. Epub 2010 Mar 22.

45.

Retinoid-suppressed phosphorylation of RARalpha mediates the differentiation pathway of osteosarcoma cells.

Luo P, Yang X, Ying M, Chaudhry P, Wang A, Shimada H, May WA, Adams GB, Mock D, Triche TJ, He Q, Wu L.

Oncogene. 2010 May 13;29(19):2772-83. doi: 10.1038/onc.2010.50. Epub 2010 Mar 1.

PMID:
20190807
46.

Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning.

Wu CC, Asgharzadeh S, Triche TJ, D'Argenio DZ.

Bioinformatics. 2010 Mar 15;26(6):807-13. doi: 10.1093/bioinformatics/btq044. Epub 2010 Feb 4.

47.

Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.

Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ.

J Clin Oncol. 2010 Mar 1;28(7):1240-6. doi: 10.1200/JCO.2008.21.1268. Epub 2010 Feb 1.

48.

Functional genomic analysis of peripheral blood during early acute renal allograft rejection.

Günther OP, Balshaw RF, Scherer A, Hollander Z, Mui A, Triche TJ, Freue GC, Li G, Ng RT, Wilson-McManus J, McMaster WR, McManus BM, Keown PA; Biomarkers in Transplantation Team.

Transplantation. 2009 Oct 15;88(7):942-51. doi: 10.1097/TP.0b013e3181b7ccc6.

PMID:
19935467
49.

Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation.

Wang A, Alimova IN, Luo P, Jong A, Triche TJ, Wu L.

FASEB J. 2010 Mar;24(3):833-43. doi: 10.1096/fj.09-142976. Epub 2009 Nov 16.

50.

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE.

Mol Cancer Ther. 2009 Nov;8(11):3024-35. doi: 10.1158/1535-7163.MCT-09-0365. Epub 2009 Nov 3.

Supplemental Content

Loading ...
Support Center